Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.9M | $33.7M | $40.7M | $46.6M | $57.1M | $73.0M | $86.1M | $89.8M |
| Cost of revenue | $3.7M | $4.1M | $11.6M | $16.9M | $20.7M | $26.6M | $27.1M | $29.6M |
| Gross profit | $19.2M | $29.7M | $29.1M | $29.7M | $36.4M | $46.4M | $59.0M | $60.3M |
| Gross margin | 83.8% | 87.9% | 71.6% | 63.7% | 63.7% | 63.5% | 68.5% | 67.1% |
| R&D | $0 | $2.8M | $4.9M | $7.1M | $0 | $0 | $0 | $0 |
| Operating income | −$40.6M | −$24.0M | −$36.5M | −$50.7M | −$41.6M | −$20.6M | −$15.0M | −$18.3M |
| EBITDA | −$35.0M | −$19.1M | −$31.6M | −$30.2M | −$28.8M | −$6.6M | $1.2M | −$3.2M |
| Net income | −$42.6M | −$26.0M | −$38.0M | −$53.0M | −$43.1M | −$22.4M | −$17.4M | −$19.2M |
| Net margin | -185.7% | -77.1% | -93.5% | -113.6% | -75.5% | -30.7% | -20.2% | -21.4% |
| EPS (diluted) | -2.10 | -0.64 | -0.76 | -0.96 | -0.66 | -0.34 | -0.25 | -0.24 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $133M | $0.19 | $0.19–$0.19 | 1 |
| 2027 | $169M | $0.28 | $0.28–$0.28 | 1 |
Forward consensus · source: Financial Modeling Prep
DIGNITANA AB, MALMO ORD
No one on the platform currently holds DIZTF.
No tracked institution reports a position in DIZTF as of their last filing.
No one on the platform has traded DIZTF yet.
| $19M |
| — |
| KBBTFKubota Pharmaceutical Holdings Co., Ltd. | $0.96 | +0.00% | $24M | — |
| SRNEQSorrento Therapeutics, Inc. | $0.03 | +3.45% | $17M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.